Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13730894 | 0.78 | KDM4E (0.49) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL8040200 | 0.78 | SLC9A1 (0.48) | POLBMAPK1ATMKDM4EKCNMA1 | |
| SCHEMBL3282387 | 0.78 | KDM4E (0.49) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL28390322 | 0.78 | KDM4E (0.49) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL751995 | 0.73 | KDM4E (0.45) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL6274820 | 0.73 | KDM4E (0.45) | POLBMAPK1ATMKDM4EKCNMA1 | |
| SCHEMBL5921930 | 0.73 | KDM4E (0.45) | POLBMAPK1ATMKDM4EKCNMA1 | |
| SCHEMBL5921928 | 0.72 | KDM4E (0.44) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL31464931 | 0.71 | FGFR1 (0.47) | POLBMAPK1ATMKDM4EFGFR1 | |
| SCHEMBL5921943 | 0.70 | KDM4E (0.41) | POLBMAPK1ATMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160001370-A1 | REDUCING AGENTS FOR SILVER MORPHOLOGY CONTROL | CARESTREAM HEALTH, INC. | 2016-01-07 | — | — | US | claimed |
| EP-1265878-B1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-13 | — | — | EP | claimed |
| EP-1882690-A2 | A process for the preparation of epothilone analogs and intermediates | Bristol-Myers Squibb Pharma Company (US) | 2008-01-30 | — | — | EP | claimed |
| US-RE39356-E1 | Process for the preparation of epothilone analogs | BRISTOL-MYERS SQUIBB CO. (US) | 2006-10-17 | — | — | US | claimed |
| US-6518421-B1 | Coupling agent for such reaction and palladium catalyst for lactonization | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-11 | — | — | US | claimed |
| US-20030004338-A1 | Process for the preparation of epothilone analogs | R-PHARM US OPERATING LLC | 2003-01-02 | — | — | US | claimed |
| EP-1265878-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILINE ANALOGS AND INTERMEDIATES | Bristol-Myers Squibb Company (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2002060904-A2 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2001070716-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2016003681-A1 | REDUCING AGENTS FOR SILVER MORPHOLOGY CONTROL | CARESTREAM HEALTH, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160001370-A1 | REDUCING AGENTS FOR SILVER MORPHOLOGY CONTROL | CARESTREAM HEALTH, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160001370-A1 | REDUCING AGENTS FOR SILVER MORPHOLOGY CONTROL | CARESTREAM HEALTH, INC. | 2016-01-07 | — | — | US | disclosed |
| EP-1265878-B1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-1882690-A2 | A process for the preparation of epothilone analogs and intermediates | Bristol-Myers Squibb Pharma Company (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20030004338-A1 | Process for the preparation of epothilone analogs | R-PHARM US OPERATING LLC | 2003-01-02 | — | — | US | disclosed |
| EP-1265878-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILINE ANALOGS AND INTERMEDIATES | Bristol-Myers Squibb Company (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020188014-A1 | Polymorphs of an epothilone analog | R-PHARM US OPERATING LLC | 2002-12-12 | — | — | US | disclosed |
| WO-2002060904-A2 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002014323-A2 | POLYMORPHS OF AN EPOTHILONE ANALOG | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001070716-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188014-A1 | Polymorphs of an epothilone analog | CYP11B1, CYP11B2, PTGER1 | POLB 1430/4885MAPK1 2686/4885ATM 4569/4885 |
| US-20030004338-A1 | Process for the preparation of epothilone analogs | DHPS, SQLE, NOTUM | POLB 1154/4885MAPK1 4034/4885ATM 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.